Sands BE - Search Results

1

Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease.

Siegel CA, Siegel LS, Hyams JS, Kugathasan S, Markowitz J, Rosh JR, Leleiko N, Mack DR, Crandall W, Evans J, Keljo DJ, Otley AR, Oliva-Hemker M, Farrior S, Langton CR, Wrobel IT, Wahbeh G, Quiros JA, Silber G, Bahar RJ, Sands BE, Dubinsky MC. Siegel CA, et al. Among authors: sands be. Inflamm Bowel Dis. 2011 Jan;17(1):30-8. doi: 10.1002/ibd.21386. Epub 2010 Sep 1. Inflamm Bowel Dis. 2011. PMID: 20812335 Free PMC article.

2

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, Podolsky DK. Sands BE, et al. Inflamm Bowel Dis. 2001 May;7(2):83-8. doi: 10.1097/00054725-200105000-00001. Inflamm Bowel Dis. 2001. PMID: 11383595 Clinical Trial.

3

Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease.

Sands BE, Winston BD, Salzberg B, Safdi M, Barish C, Wruble L, Wilkins R, Shapiro M, Schwertschlag US; RHIL-11 Crohn's Study group. Sands BE, et al. Aliment Pharmacol Ther. 2002 Mar;16(3):399-406. doi: 10.1046/j.1365-2036.2002.01179.x. Aliment Pharmacol Ther. 2002. PMID: 11876692 Free article. Clinical Trial.

4

Guidelines for immunizations in patients with inflammatory bowel disease.

Sands BE, Cuffari C, Katz J, Kugathasan S, Onken J, Vitek C, Orenstein W. Sands BE, et al. Inflamm Bowel Dis. 2004 Sep;10(5):677-92. doi: 10.1097/00054725-200409000-00028. Inflamm Bowel Dis. 2004. PMID: 15472534

5

A survey of methodological variation in the Crohn's disease activity index.

Sands BE, Ooi CJ. Sands BE, et al. Inflamm Bowel Dis. 2005 Feb;11(2):133-8. doi: 10.1097/00054725-200502000-00006. Inflamm Bowel Dis. 2005. PMID: 15677906

6

Review article: practical management of inflammatory bowel disease patients taking immunomodulators.

Siegel CA, Sands BE. Siegel CA, et al. Among authors: sands be. Aliment Pharmacol Ther. 2005 Jul 1;22(1):1-16. doi: 10.1111/j.1365-2036.2005.02520.x. Aliment Pharmacol Ther. 2005. PMID: 15963074 Free article. Review.

7

Risk factors for colorectal cancer in Crohn's colitis: a case-control study.

Siegel CA, Sands BE. Siegel CA, et al. Among authors: sands be. Inflamm Bowel Dis. 2006 Jun;12(6):491-6. doi: 10.1097/00054725-200606000-00008. Inflamm Bowel Dis. 2006. PMID: 16775493

8

Risks and benefits of infliximab for the treatment of Crohn's disease.

Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE. Siegel CA, et al. Among authors: sands be. Clin Gastroenterol Hepatol. 2006 Aug;4(8):1017-24; quiz 976. doi: 10.1016/j.cgh.2006.05.020. Epub 2006 Jul 14. Clin Gastroenterol Hepatol. 2006. PMID: 16843733

9

Possible association between isotretinoin and inflammatory bowel disease.

Reddy D, Siegel CA, Sands BE, Kane S. Reddy D, et al. Among authors: sands be. Am J Gastroenterol. 2006 Jul;101(7):1569-73. doi: 10.1111/j.1572-0241.2006.00632.x. Am J Gastroenterol. 2006. PMID: 16863562

10

Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.

Sands BE, Kozarek R, Spainhour J, Barish CF, Becker S, Goldberg L, Katz S, Goldblum R, Harrigan R, Hilton D, Hanauer SB. Sands BE, et al. Inflamm Bowel Dis. 2007 Jan;13(1):2-11. doi: 10.1002/ibd.20014. Inflamm Bowel Dis. 2007. PMID: 17206633 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

359 results

Search Page